201 related articles for article (PubMed ID: 32393412)
21. Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
Iwata N; Ishigooka J; Naoi I; Matsumoto M; Kanamori Y; Nakamura H; Higuchi T
CNS Drugs; 2020 Jan; 34(1):103-116. PubMed ID: 31883082
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.
Citrome L; Weiden PJ; McEvoy JP; Correll CU; Cucchiaro J; Hsu J; Loebel A
CNS Spectr; 2014 Aug; 19(4):330-9. PubMed ID: 24330868
[TBL] [Abstract][Full Text] [Related]
23. Physiologically-Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan.
Sun L; von Moltke L; Rowland Yeo K
CPT Pharmacometrics Syst Pharmacol; 2020 Feb; 9(2):106-114. PubMed ID: 31919994
[TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.
Durgam S; Greenberg WM; Li D; Lu K; Laszlovszky I; Nemeth G; Migliore R; Volk S
Psychopharmacology (Berl); 2017 Jan; 234(2):199-209. PubMed ID: 27807604
[TBL] [Abstract][Full Text] [Related]
25. Olanzapine/Samidorphan: First Approval.
Paik J
Drugs; 2021 Aug; 81(12):1431-1436. PubMed ID: 34304374
[TBL] [Abstract][Full Text] [Related]
26. Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet.
Sun L; Yagoda S; Du Y; von Moltke L
Drug Des Devel Ther; 2019; 13():2941-2955. PubMed ID: 31686778
[TBL] [Abstract][Full Text] [Related]
27. Effect of Food on the Pharmacokinetics of a Combination of Olanzapine and Samidorphan.
Sun L; McDonnell D; Liu J; von Moltke L
Clin Pharmacol Drug Dev; 2019 May; 8(4):503-510. PubMed ID: 30921503
[TBL] [Abstract][Full Text] [Related]
28. Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.
Correll CU; Stein E; Graham C; DiPetrillo L; Akerman S; Stanford AD; Jiang Y; Yagoda S; McDonnell D; Hopkinson C
Schizophr Bull; 2023 Mar; 49(2):454-463. PubMed ID: 36305696
[TBL] [Abstract][Full Text] [Related]
29. An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.
Wang HH; Cai M; Wang HN; Chen YC; Zhang RG; Wang Y; McAlonan GM; Bai YH; Wu WJ; Guo L; Zhang YH; Tan QR; Zhang ZJ
J Psychiatr Res; 2017 Feb; 85():59-65. PubMed ID: 27837658
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
Sun L; McDonnell D; von Moltke L
Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514
[TBL] [Abstract][Full Text] [Related]
31. Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination.
Sun L; von Moltke L; Rowland Yeo K
Clin Pharmacokinet; 2021 May; 60(5):637-647. PubMed ID: 33313995
[TBL] [Abstract][Full Text] [Related]
32. Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet.
Sun L; Barter Z; von Moltke L; Rowland Yeo K
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1071-1080. PubMed ID: 34185436
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study.
Maciulis V; Bitter I; Milasiunas R; Dembinskas A; Radavicius L; Kaunas A; Dossenbach M; Walker D
Curr Ther Res Clin Exp; 2004 Jan; 65(1):57-69. PubMed ID: 24936104
[TBL] [Abstract][Full Text] [Related]
34. A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study.
Niitsu T; Hata T; Nishimoto M; Hosoda Y; Kimura A; Oda Y; Suzuki M; Takase N; Seki R; Fujita K; Endo M; Yoshida T; Inoue M; Hattori N; Murakami T; Imamura Y; Ogawa K; Fukami G; Sato T; Kawasaki Y; Hashimoto T; Ishikawa M; Shiina A; Kanahara N; Iyo M;
Asian J Psychiatr; 2020 Oct; 53():102369. PubMed ID: 32920492
[TBL] [Abstract][Full Text] [Related]
35. Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.
Monahan C; McCoy L; Powell J; Gums JG
Ann Pharmacother; 2022 Sep; 56(9):1049-1057. PubMed ID: 35040357
[TBL] [Abstract][Full Text] [Related]
36. Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine-Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study.
Sun L; McDonnell D; Liu J; von Moltke L
Clin Pharmacol Drug Dev; 2019 May; 8(4):459-466. PubMed ID: 30059196
[TBL] [Abstract][Full Text] [Related]
37. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A
Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553
[TBL] [Abstract][Full Text] [Related]
38. Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study.
Citrome L; O'Malley SS; McDonnell D; Jiang Y; Simmons AC; Berry MP; Dipetrillo LE
Innov Clin Neurosci; 2019 May; 16(5-6):15-21. PubMed ID: 31440397
[No Abstract] [Full Text] [Related]
39. Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder.
Thase ME; Stanford AD; Memisoglu A; Martin W; Claxton A; Bodkin JA; Trivedi MH; Fava M; Yu M; Pathak S
Neuropsychopharmacology; 2019 Dec; 44(13):2268-2276. PubMed ID: 31254971
[TBL] [Abstract][Full Text] [Related]
40. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.
Sanger TM; Grundy SL; Gibson PJ; Namjoshi MA; Greaney MG; Tohen MF
J Clin Psychiatry; 2001 Apr; 62(4):273-81. PubMed ID: 11379842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
